The bone marrow transplant market is anticipated to flourish at an average CAGR of 3.4% between 2023 and 2033. The market is expected to hold a market share of US$ 14.86 billion by 2033, while the market is likely to reach a value of US$ 10.65 billion in 2023. A historical CAGR of 2.5% has been recorded by the experts of Future Market Insights for the market concerned.
The hematopoietic stem cell is a soft vascular tissue in the interiors of long bones, and a bone marrow transplant is identified as the procedure to replace the damaged or destroyed bone marrow with healthy bone marrow stem cells.
| Attributes | Details |
|---|---|
| Bone Marrow Transplant Market CAGR (2023 to 2033) | 3.4% |
| Bone Marrow Transplant Market Size (2023) | US$ 10.65 billion |
| Bone Marrow Transplant Market Size (2033) | US$ 14.86 billion |
The bone marrow transplant procedure is prescribed for the treatment of advanced stages of leukemia, Hodgkin, and non-Hodgkin lymphomas, multiple myeloma, aplastic and sickle cell anemia, thalassemia, and other diseases. Increasing awareness, combined with an increase in initiatives run by healthcare practitioners, is majorly responsible for the global growth of the market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market is anticipated to have mixed dynamics contributing to the bearish propulsion of the bone marrow transplant market. Several factors impacting the expansion of the market are identified during the study.
Besides the factors influencing growth, it is also identified that certain aspects can limit growth and curb the pace of growth further in the market.
Drivers:
Restraints:
| Country | Revenue Share % (2022) |
|---|---|
| United States | 30.3% |
| Germany | 11.9% |
| Japan | 2/0% |
| North America | 32.3% |
| Europe | 53.1% |
| Country | CAGR % (2023 to 2033) |
|---|---|
| China | 4.2% |
| India | 3.4% |
| United Kingdom | 2.4% |
| Australia | 3.1% |
North America is projected to secure steady bone marrow transplant market growth during the forecast period. The region cumulatively held 32.3% market share of the global bone marrow transplant market in 2022.
The factors attributing to the growth can be mentioned as follows:
Europe is projected to dominate the global market for bone marrow transplants during the forecast period. At present, Europe holds 53.1% of the total market share for bone marrow transplants worldwide in 2022.
The reasons owing for such extensive market expansion are mentioned below:
Principal Consultant
| Category | By Transplant Type |
|---|---|
| Leading Segment | Autologous |
| Market Share (2022) | 54.5% |
| Category | By End User |
|---|---|
| Leading Segment | Hospital |
| Market Share (2022) | 90.3% |
The start-ups in the bone marrow transplant market are indulging in collaborations and continually making innovations to stem cell transplant procedures to further make it convenient and cost-efficient for the population.
| Company Name | Magenta Therapeutics, Cambridge (United States) |
|---|---|
| Total Funding | US$ 151 million |
| Description | Developed stem cell-based therapies for autoimmune disease, genetic blood disorders, and cancer. The company has developed stem cell transplants by using targeted antibodies, stem cell harvesting using new biologic agents, and increasing stem cell numbers by targeting self-renewal pathways. |
| Company Name | Kiadis Pharma, Amsterdam (Netherlands) |
|---|---|
| Total Funding | US$ 33 million |
| Description | Kiadis Pharma is a developer of therapeutic solutions for hematopoietic stem cell transplants. It is focused on developing solutions for complications and limitations of hematopoietic stem cell transplants (HSCT) in blood cancer patients. The company uses all depleted T-cell immunotherapeutics (ATIR) to support the patient’s newly transplanted immune system before it becomes fully functional. This enables better acceptance of even haploidentical (or lower) stem cell donors. Kiadis is investigating the use of ATIR in leukemia and thalassemia. |
| Company Name | Talaris, Boston |
|---|---|
| Total Funding | US$ 215 million |
| Description | Talaris Therapeutics is involved in developing single-dose cell therapy to treat living donor kidney transplant tolerance. They have developed a proprietary technology that allows candidates for bone marrow transplants to receive hematopoietic stem cells (HSCs). The lead candidate, FCR001, is in phase III clinical trial, which is being investigated for living donor kidney transplant tolerance. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The bone marrow transplant market is highly competitive and consists of several leading players. To increase their global market presence, market leaders are engaging in various product launches, mergers and acquisitions, and development activities focusing on orthopedic surgical treatments.
Recent Developments
Some Recent Developments Identified in the Analysis are:
The market is anticipated to be valued at US$ 10.65 billion in 2023.
The global market advanced at a 2.5% HCAGR from 2018 to 2022.
Up until 2033, the market is anticipated to thrive at a CAGR of 3.4%.
Potentially holding 32.3% of the market in North America.
The market has been dominated by Europe, 53.1%.
By 2033, the market is anticipated to be worth US$14.86 billion.
The autologous category to escalate to a market share of 54.5% in 2023.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Transplant Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Transplant Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Transplant Type, 2023 to 2033
5.3.1. Autologous
5.3.2. Allogeneic
5.4. Y-o-Y Growth Trend Analysis By Transplant Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Transplant Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2023 to 2033
6.3.1. Leukemia
6.3.2. Lymphoma
6.3.3. Myeloma
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Disease Indication, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End-User , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User , 2023 to 2033
7.3.1. Hospitals
7.3.2. Multispecialty Clinics
7.3.3. Ambulatory Surgical Centers
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By End-User , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End-User , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA.
9.2.1.2. Canada
9.2.2. By Transplant Type
9.2.3. By Disease Indication
9.2.4. By End-User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Transplant Type
9.3.3. By Disease Indication
9.3.4. By End-User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Transplant Type
10.2.3. By Disease Indication
10.2.4. By End-User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Transplant Type
10.3.3. By Disease Indication
10.3.4. By End-User
10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Transplant Type
11.2.3. By Disease Indication
11.2.4. By End-User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Transplant Type
11.3.3. By Disease Indication
11.3.4. By End-User
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Transplant Type
12.2.3. By Disease Indication
12.2.4. By End-User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Transplant Type
12.3.3. By Disease Indication
12.3.4. By End-User
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Transplant Type
13.2.3. By Disease Indication
13.2.4. By End-User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Transplant Type
13.3.3. By Disease Indication
13.3.4. By End-User
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Transplant Type
14.2.3. By Disease Indication
14.2.4. By End-User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Transplant Type
14.3.3. By Disease Indication
14.3.4. By End-User
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Transplant Type
15.2.3. By Disease Indication
15.2.4. By End-User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Transplant Type
15.3.3. By Disease Indication
15.3.4. By End-User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA.
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Transplant Type
16.1.2.2. By Disease Indication
16.1.2.3. By End-User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Transplant Type
16.2.2.2. By Disease Indication
16.2.2.3. By End-User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Transplant Type
16.3.2.2. By Disease Indication
16.3.2.3. By End-User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Transplant Type
16.4.2.2. By Disease Indication
16.4.2.3. By End-User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Transplant Type
16.5.2.2. By Disease Indication
16.5.2.3. By End-User
16.6. United Kingdom.
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Transplant Type
16.6.2.2. By Disease Indication
16.6.2.3. By End-User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Transplant Type
16.7.2.2. By Disease Indication
16.7.2.3. By End-User
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Transplant Type
16.8.2.2. By Disease Indication
16.8.2.3. By End-User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Transplant Type
16.9.2.2. By Disease Indication
16.9.2.3. By End-User
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Transplant Type
16.10.2.2. By Disease Indication
16.10.2.3. By End-User
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Transplant Type
16.11.2.2. By Disease Indication
16.11.2.3. By End-User
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Transplant Type
16.12.2.2. By Disease Indication
16.12.2.3. By End-User
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Transplant Type
16.13.2.2. By Disease Indication
16.13.2.3. By End-User
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Transplant Type
16.14.2.2. By Disease Indication
16.14.2.3. By End-User
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Transplant Type
16.15.2.2. By Disease Indication
16.15.2.3. By End-User
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Transplant Type
16.16.2.2. By Disease Indication
16.16.2.3. By End-User
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Transplant Type
16.17.2.2. By Disease Indication
16.17.2.3. By End-User
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Transplant Type
16.18.2.2. By Disease Indication
16.18.2.3. By End-User
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Transplant Type
16.19.2.2. By Disease Indication
16.19.2.3. By End-User
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Transplant Type
16.20.2.2. By Disease Indication
16.20.2.3. By End-User
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Transplant Type
16.21.2.2. By Disease Indication
16.21.2.3. By End-User
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2022
16.22.2.1. By Transplant Type
16.22.2.2. By Disease Indication
16.22.2.3. By End-User
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2022
16.23.2.1. By Transplant Type
16.23.2.2. By Disease Indication
16.23.2.3. By End-User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Transplant Type
17.3.3. By Disease Indication
17.3.4. By End-User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Lonza Group Ltd.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Merck Millipore Corporation
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Sanofi-Aventis LLC.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. AllCells LLC.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. STEMCELL Technologies
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. ATCC Inc.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Hemacare Corporation
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Cellular Dynamics International
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. ReachBio LLC.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Conversant Bio, ABM Inc.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. PromoCell GmbH
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.12. Cruline Human biospecimen PRO
18.1.12.1. Overview
18.1.12.2. Product Portfolio
18.1.12.3. Profitability by Market Segments
18.1.12.4. Sales Footprint
18.1.12.5. Strategy Overview
18.1.12.5.1. Marketing Strategy
18.1.13. Lifeline Cell Technology
18.1.13.1. Overview
18.1.13.2. Product Portfolio
18.1.13.3. Profitability by Market Segments
18.1.13.4. Sales Footprint
18.1.13.5. Strategy Overview
18.1.13.5.1. Marketing Strategy
18.1.14. Mesoblast Ltd.
18.1.14.1. Overview
18.1.14.2. Product Portfolio
18.1.14.3. Profitability by Market Segments
18.1.14.4. Sales Footprint
18.1.14.5. Strategy Overview
18.1.14.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Bone Marrow Transplant Market
